RICHARDSON, Texas, Aug. 21 /PRNewswire/ -- Zyvex Labs today announced its first company spinout: NanoMed, Inc. The new company was started by Rob Burgess, PhD, former Vice President of Research & Development at Zyvex Instruments, and Gareth Hughes, PhD, former Group Leader of Life Sciences at Zyvex Corporation.
NanoMed is focused on the application of nanotechnology in Life Sciences. The company seeks to apply nanoparticle technologies for the development of research grade reagents and cutting-edge therapeutics. In addition, NanoMed possesses a strong collection of nanotechnology platforms that are currently available for licensing. The new company leverages Zyvex's existing Life Science patents, proprietary methods, and core technologies.
"We are delighted to obtain assignment of the nanoparticle dispersion intellectual property from Zyvex Labs," said Rob Burgess, Ph.D., NanoMed's Co-Founder and Chairman of the Board. "The application of Zyvex Performance Materials' Kentera(TM) and other polymers for functionalizing carbon nanotubes will play an integral role in solidifying NanoMed's portfolio of cutting-edge nanotechnologies as they relate to the biomedical sciences. We look forward to continuing a productive partnership with Zyvex Labs and Zyvex Performance Materials."
"Rob is a focused leader with outstanding technology development skills," said Zyvex Founder Jim Von Ehr. "He also has a proven track record in growing businesses. I expect to see exciting new products from this new venture."
NanoMed's focus centers around the functionalization and specific delivery of nanoparticles for applications in various biomedical markets, including the research, diagnostics, therapeutics, and veterinary sectors. In collaboration with their strategic partners, NanoMed researchers have developed promising technologies that will allow for the effective use of nanotechnology-based solutions to address a variety of issues across multiple scientific disciplines, including basic biomedical research and applied science related to disorders such as cancer and infectious diseases.
Other founders include Rocky Draper, PhD, Professor at the University of Texas at Dallas, and Ellen Vitetta, PhD, Professor and Director of the Cancer Immunobiology Center at the University of Texas Southwestern Medical Center in Dallas.
More information about NanoMed's technologies and business strategy can be found at http://www.nanomedinc.com.
CONTACT: Rob Burgess, Ph.D., Chairman of the Board of NanoMed, Inc.,+1-951-970-8525, email@example.com